Latest Cyberonics Inc (CYBX) Headlines Insider
Post# of 34
Posted On: 03/13/2014 7:26:37 AM
Latest Cyberonics Inc (CYBX) Headlines
Insider Trading Alert - VRSN, TUP And CYBX Traded By Insiders
at The Street - Fri Mar 07, 10:00AM CST
Stocks with insider trader activity include VRSN, TUP and CYBX
Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders
at The Street - Thu Mar 06, 1:00PM CST
Stocks with insider trader activity include IP, CYBX and JAZZ
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
Cyberonics Q3 sales short
at Investor's Business Daily - Thu Feb 20, 6:14PM CST
Implantable medical device maker Cyberonics (CYBX) said fiscal Q3 earnings per share rose 9% compared to a year ago, to 51 cents, beating analyst estimates by 2 cents. Revenue also rose 9% to $68.2 mil, just missing views for $69.7 mil. The company...
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy®
PR Newswire - Thu Feb 20, 6:15AM CST
Cyberonics, Inc. (NASDAQ:CYBX) announced today the CE Mark (Conformité Européenne) approval in Europe for the AspireSR generator, the novel sixth-generation VNS Therapy generator.
Cyberonics Reports Fiscal 2014 Third Quarter Results
PR Newswire - Thu Feb 20, 6:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter, and year-to-date, ended January 24, 2014.
Cyberonics To Participate In Upcoming Investor Conferences
PR Newswire - Wed Feb 19, 3:00PM CST
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences.
Pacific Biosciences (PACB) Jumps: Stock Moves 8.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:46AM CST
Pacific Biosciences was a big mover last session, with shares rising over 8%.
Teleflex Recalls Tracheal Tube - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 1:50PM CST
Teleflex Medical has announced a worldwide voluntary recall of its ISIS HVT Tracheal Tube.
Neiman Marcus Launches Exclusive Lela Rose Tabletop Capsule Collection
PR Newswire - Thu Feb 13, 7:00AM CST
Today, Neiman Marcus announced the launch of a Lela Rose tabletop collection available exclusively at NeimanMarcus.com, marking the fashion designer's first collaboration in the home category.
Cepheid Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 2:20PM CST
On Feb 4, Zacks Investment Research downgraded Cepheid to a Zacks Rank #5 (Strong Sell).
The Zacks Analyst Blog Highlights:Henry Schein, Cyberonics, DexCom, Regeneron Pharmaceuticals and Bayer
PR Newswire - Tue Feb 11, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Henry Schein Inc. (Nasdaq:HSIC-Free Report), Cyberonics Inc. (Nasdaq:CYBX-Free Report), DexCom, Inc. (Nasdaq
XCM-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report) and Bayer (OTC:BAYRY-Free Report).
Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:41AM CST
This hike is expected to result in 385 million new grant opportunities for researchers.
Insider Trading Alert - TER, CYBX, NSC, PLCM And MTW Traded By Insiders
at The Street - Mon Feb 10, 9:30AM CST
Stocks with insider trader activity include TER, CYBX, NSC, PLCM and MTW
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
Cyberonics To Report Fiscal Year 2014 Third Quarter Results And Host Webcast And Conference Call On February 20, 2014
PR Newswire - Tue Feb 04, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the third quarter ended January 24, 2014, of its fiscal year ending April 25, 2014, on Thursday, February 20, 2014, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
The Future of Enterprise Communications from a Customer Perspective
PR Newswire - Thu Jan 30, 6:26AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Leading Economic Indicator: U.S. Economic Recovery Likely To Continue Restrained Pace Throughout 2014
PR Newswire - Tue Jan 28, 8:06AM CST
The first Chemical Activity Barometer (CAB) reading of 2014 strengthened slightly, pointing to continued growth and an improving U.S. economy throughout 2014. The barometer in January ticked up to 94.0, increasing 0.2 points over December on a three-month moving average (3MMA) basis. This marks the ninth consecutive monthly gain for the CAB, which is now up 2.6 percent over a year ago. This growth is at a more moderate pace since the 0.4 percent gain last seen in September of 2013. The Chemical Activity Barometer is an established leading economic indicator, shown to lead U.S. business cycles by an average of eight months at cycle peaks, and four months at cycle troughs.
Insider Trading Alert - VRSN, TUP And CYBX Traded By Insiders
at The Street - Fri Mar 07, 10:00AM CST
Stocks with insider trader activity include VRSN, TUP and CYBX
Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders
at The Street - Thu Mar 06, 1:00PM CST
Stocks with insider trader activity include IP, CYBX and JAZZ
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
Cyberonics Q3 sales short
at Investor's Business Daily - Thu Feb 20, 6:14PM CST
Implantable medical device maker Cyberonics (CYBX) said fiscal Q3 earnings per share rose 9% compared to a year ago, to 51 cents, beating analyst estimates by 2 cents. Revenue also rose 9% to $68.2 mil, just missing views for $69.7 mil. The company...
Cyberonics Announces CE Mark Approval Of The AspireSR(TM) Generator For VNS Therapy®
PR Newswire - Thu Feb 20, 6:15AM CST
Cyberonics, Inc. (NASDAQ:CYBX) announced today the CE Mark (Conformité Européenne) approval in Europe for the AspireSR generator, the novel sixth-generation VNS Therapy generator.
Cyberonics Reports Fiscal 2014 Third Quarter Results
PR Newswire - Thu Feb 20, 6:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter, and year-to-date, ended January 24, 2014.
Cyberonics To Participate In Upcoming Investor Conferences
PR Newswire - Wed Feb 19, 3:00PM CST
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences.
Pacific Biosciences (PACB) Jumps: Stock Moves 8.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:46AM CST
Pacific Biosciences was a big mover last session, with shares rising over 8%.
Teleflex Recalls Tracheal Tube - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 1:50PM CST
Teleflex Medical has announced a worldwide voluntary recall of its ISIS HVT Tracheal Tube.
Neiman Marcus Launches Exclusive Lela Rose Tabletop Capsule Collection
PR Newswire - Thu Feb 13, 7:00AM CST
Today, Neiman Marcus announced the launch of a Lela Rose tabletop collection available exclusively at NeimanMarcus.com, marking the fashion designer's first collaboration in the home category.
Cepheid Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 2:20PM CST
On Feb 4, Zacks Investment Research downgraded Cepheid to a Zacks Rank #5 (Strong Sell).
The Zacks Analyst Blog Highlights:Henry Schein, Cyberonics, DexCom, Regeneron Pharmaceuticals and Bayer
PR Newswire - Tue Feb 11, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Henry Schein Inc. (Nasdaq:HSIC-Free Report), Cyberonics Inc. (Nasdaq:CYBX-Free Report), DexCom, Inc. (Nasdaq
XCM-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report) and Bayer (OTC:BAYRY-Free Report). Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:41AM CST
This hike is expected to result in 385 million new grant opportunities for researchers.
Insider Trading Alert - TER, CYBX, NSC, PLCM And MTW Traded By Insiders
at The Street - Mon Feb 10, 9:30AM CST
Stocks with insider trader activity include TER, CYBX, NSC, PLCM and MTW
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Friday
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
Cyberonics To Report Fiscal Year 2014 Third Quarter Results And Host Webcast And Conference Call On February 20, 2014
PR Newswire - Tue Feb 04, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the third quarter ended January 24, 2014, of its fiscal year ending April 25, 2014, on Thursday, February 20, 2014, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
The Future of Enterprise Communications from a Customer Perspective
PR Newswire - Thu Jan 30, 6:26AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Leading Economic Indicator: U.S. Economic Recovery Likely To Continue Restrained Pace Throughout 2014
PR Newswire - Tue Jan 28, 8:06AM CST
The first Chemical Activity Barometer (CAB) reading of 2014 strengthened slightly, pointing to continued growth and an improving U.S. economy throughout 2014. The barometer in January ticked up to 94.0, increasing 0.2 points over December on a three-month moving average (3MMA) basis. This marks the ninth consecutive monthly gain for the CAB, which is now up 2.6 percent over a year ago. This growth is at a more moderate pace since the 0.4 percent gain last seen in September of 2013. The Chemical Activity Barometer is an established leading economic indicator, shown to lead U.S. business cycles by an average of eight months at cycle peaks, and four months at cycle troughs.
(0)
(0)Cyberonics Inc. (CYBX) Stock Research Links
Scroll down for more posts ▼